Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

NCT06414889 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

4

Enrollment

OTHER

Sponsor class

Conditions

RUNX1 Familial Platelet Disorder

Interventions

DRUG: G-CSF (filgrastim or biosimilar)
PROCEDURE: Apheresis
DRUG: Plerixafor

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]